Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
about
Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseGenotypes Affecting the Pharmacokinetics of Anticancer Drugs.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.The safety of non-biological treatments in Ulcerative Colitis.A brighter future for the implementation of pharmacogenomic testing.The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.Inflammatory Bowel Disease in Childhood and Adolescence.Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations.Monitoring thiopurine metabolites in inflammatory bowel disease.From genomic medicine to precision medicine: highlights of 2015.Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing.Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.Benefit of pre-emptive pharmacogenetic information on clinical outcome.Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project.Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study.PemphigusRevisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q30244222-B15ABC87-5C64-49CA-97E2-ACD5FCCEB751Q30492009-56D8A167-01C1-48DB-8C25-E53DE8C7D626Q33674158-B92E2FD8-336A-48B4-9B58-3F6570734DCEQ37685527-CB84ABBB-79CB-47E3-8406-1C68976DD4D1Q38417177-C3DB248F-81C7-459F-AD91-A81EBEC7A8B8Q38563075-FC563F88-A130-4488-A4FF-1754BEC5F44AQ38712266-CD98CB18-6AF6-46EE-A451-38B9B6F42965Q38728164-402B85D9-F271-4B6B-83B9-7D2C6FA73D82Q38826219-7C7DD497-1DF4-4707-A5C5-947DF5F7AA60Q39043462-7B0AF768-E562-417F-9DAD-B9BF92721AA9Q39062032-993FC246-E443-46C7-A8A8-BD3C14074B99Q39119181-5695E382-67F1-4D8F-8924-DC5CE22469F0Q39361742-91E06298-8198-4AB9-B9AB-5750070EE406Q40044141-958B7BD5-535E-42DB-8403-06D9740D7DF8Q40368410-24C465DD-FB4F-4B34-B183-42D8886DAD1CQ41642129-8BB1241A-7132-4675-B101-83FC4648FDA4Q42537218-3F5CF2D3-9FBA-434A-832A-E97C0275C3BAQ47847637-D6C6E13D-C997-48D7-98DC-A055C06C8831Q48144647-6FF57C58-6E27-4E66-917C-E05DA28AF1D0Q48144709-4B46C39E-CFA8-462E-9A60-277F8B56254DQ48223506-BC22035B-DCF3-4AAE-89D1-D85747370088Q49228777-62E1725D-CDB1-45A6-A85E-B4A6922FF96CQ49612005-F46B6E5C-9228-462A-809B-C654243790F3Q49918608-B22BE7FE-3459-4668-A393-99D829AB14F7Q49999241-0BE7E0F6-F0B0-4AC5-A7FE-D484C6A64061Q51647916-D879A360-C989-46EF-B2F5-A0C248F73C8FQ55259199-F8F27D6A-1C22-4297-ACAB-636A3BB23367Q56603745-BD2354FE-BC67-4C19-87A1-D798E75ED5B6Q57817595-D8520A80-931C-45EC-83C9-6A158A251819
P2860
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@ast
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@en
type
label
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@ast
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@en
prefLabel
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@ast
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@en
P2093
P50
P1433
P1476
Identification of Patients Wit ...... of Inflammatory Bowel Disease.
@en
P2093
Andre L M Verbeek
Corine J van Marrewijk
Dennis R Wong
Dirk J de Jong
Hans Scheffer
Luc J J Derijks
Marieke J H Coenen
Olaf H Klungel
Piet M Hooymans
Rene H M te Morsche
P304
P356
10.1053/J.GASTRO.2015.06.002
P407
P577
2015-06-10T00:00:00Z